WASHINGTON, Sept 9 (Reuters) - The chairman of the U.S.
Senate Judiciary Committee probing Mylan NV's EpiPen
price hike on Friday said its response to his query was
"incomplete," and called on the drugmaker to give more details
over how much government health insurance programs pay for the
allergy treatment.
Read more
No comments:
Post a Comment